IP Library › Granted Patent US 7,713,931
Granted Patent B2
US 7,713,931 · App. 11/895,533 · Granted May 11, 2010

Cross-linked glycopeptide-cephalosporin antibiotics

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,713,931
App. No.
11/895,533
Granted
May 11, 2010
Kind
B2
Abstract

This invention provides cross-linked glycopeptide-cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using such compounds; and processes and intermediates useful for preparing such compounds.

Claims (22)

1. A method of treating a Staphylococcus infection in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a compound of the formula:

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the Staphylococcus infection is caused by Staphylococcus aureus.

3. The method of claim 1 , wherein the Staphylococcus infection is caused by methicillin-resistant Staphylococcus aureus.

4. The method of claim 1 , wherein the Staphylococcus infection is caused by Staphylococcus epidermidis.

5. The method of claim 1 , wherein the Staphylococcus infection is caused by methicillin-resistant Staphylococcus epidermidis.

6. The method of claim 1 , wherein the compound or the pharmaceutically acceptable salt thereof is administered intravenously.

7. The method of claim 1 , wherein the compound is a hydrochloride salt.

8. A method of treating a skin and skin structure infection in a patient, the method comprising administering to the patient a therapeutically effective amount of a compound of the formula:

or a pharmaceutically acceptable salt thereof.

9. The method of claim 8 , wherein the skin and skin structure infection is caused by a Staphylococcus species.

10. The method of claim 8 , wherein the skin and skin structure infection is caused by Staphylococcus aureus.

11. The method of claim 8 , wherein the skin and skin structure infection is caused by methicillin-resistant Staphylococcus aureus.

12. The method of claim 8 , wherein the compound or the pharmaceutically acceptable salt thereof is administered intravenously.

13. The method of claim 8 , wherein the compound is a hydrochloride salt.

14. A method of treating pneumonia in a patient, the method comprising administering to the patient a therapeutically effective amount of a compound of the formula:

or a pharmaceutically acceptable salt thereof.

15. The method of claim 14 , wherein the pneumonia is caused by a Staphylococcus species.

16. The method of claim 14 , wherein the pneumonia is caused by Staphylococcus aureus.

17. The method of claim 14 , wherein the pneumonia is caused by methicillin-resistant Staphylococcus aureus.

18. The method of claim 14 , wherein the compound or the pharmaceutically acceptable salt thereof is administered intravenously.

19. The method of claim 14 , wherein the compound is a hydrochloride salt.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2014
From: THERAVANCE, INC.
To: THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC
Reel/Frame 033179/0484 →